Form4insider filings, from the source

SEC Form 4 · accession 0001567619-18-003762

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Jacob Van Naarden
Officer — Chief Business Officer
Period of report
Oct 3, 2018
Accepted (ET)
Oct 5, 2018 · 4:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockOct 3, 2018M5,500$3.648A19,200D
Common StockF2,F3Oct 3, 2018S2,000$165.1303D17,200D
Common StockF2,F4Oct 3, 2018S400$165.885D16,800D
Common StockF2,F5Oct 3, 2018S500$167.192D16,300D
Common StockF2,F6Oct 3, 2018S2,300$168.8465D14,000D
Common StockF2,F7Oct 3, 2018S300$169.40D13,700D
Common StockOct 4, 2018M4,500$3.648A18,200D
Common StockF2,F8Oct 4, 2018S600$160.6217D17,600D
Common StockF2,F9Oct 4, 2018S1,100$161.5205D16,500D
Common StockF2,F10Oct 4, 2018S1,194$162.701D15,306D
Common StockF2,F11Oct 4, 2018S1,006$163.7845D14,300D
Common StockF2,F12Oct 4, 2018S600$164.6767D13,700D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (Right to Buy)F13$3.648Oct 3, 2018M5,500D—Jun 18, 2024Common Stock5,50052,769D
Employee Stock Option (Right to Buy)F13$3.648Oct 4, 2001M4,500D—Jun 18, 2024Common Stock4,50048,269D

Explanation of responses